Annual Report 2010 Active Biotech AB (publ)

Apr 6, 2011 10:01 (CEST) 
Active Biotech's Annual Report 2010 is now available for download
atwww.activebiotech.com

The Annual Report will only be digitally distributed.


Lund, April 6, 2011

Active Biotech AB (publ)

Tomas Leanderson
President & CEO



For further information, please contact:
Göran Forsberg
Vice President Investor Relations & Business Development
Tel +46 (0)46 19 11 54


Active  Biotech AB  (NASDAQ OMX  NORDIC: ACTI)  is a  biotechnology company with
focus  on autoimmune/inflammatory diseases  and cancer. Projects  in or entering
pivotal  phase are laquinimod, an orally administered small molecule with unique
immunomodulatory  properties for the  treatment of multiple  sclerosis, TASQ for
prostate  cancer and  ANYARA for  use in  cancer targeted  therapy, primarily of
renal  cell  cancer.  In  addition,  laquinimod  is  in Phase II development for
Crohn's  and Lupus.  Further projects  in clinical  development comprise the two
orally  administered compounds, 57- 57 for SLE and Systemic Sclerosis as well as
RhuDex(TM) for RA. Please visit www.activebiotech.com  for more information.

Active Biotech AB (Corp. Reg. No. 556223-9227)
Box 724, SE-220 07 Lund
Tel: +46 46 19 20 00
Fax: +46 46 19 11 00

Active  Biotech is obligated to publish  the information contained in this press
release  in accordance with the Swedish  Securities Market Act. This information
was   provided  to  the  media  for  publication  on  April  6, 2011, at  10:00
a.m.



Annual Report 2010 Active Biotech AB (publ):
http://hugin.info/1002/R/1503893/438823pdf




This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
    other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
     originality of the information contained therein.

Source: Active Biotech via Thomson Reuters ONE

[HUG#1503893]